search
Back to results

EEG Characteristics in ECT

Primary Purpose

Electroconvulsive Therapy, Direct Current Electroencephalogram, Ketamine

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Methohexital
Sponsored by
University of New Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Electroconvulsive Therapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features
  • The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response;
  • Hamilton Depression Rating Scale 24-item (HDRS-24) > 21; and
  • Age range between 18 and 65 years of age.

Exclusion Criteria:

  • Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease);
  • Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
  • Current drug or alcohol use disorder, except for nicotine and marijuana
  • Adults unable to consent, pregnant women, prisoner
  • Non-English speakers
  • Patients that cannot tolerate Methohexital and Ketamine.

Sites / Locations

  • University of New Mexico Mental Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Methohexital

Ketamine

Arm Description

Standard of care anesthesia that does not affect slow wave characteristics

Standard of care anesthesia that suppresses slow wave characteristics

Outcomes

Primary Outcome Measures

Clinical Efficacy of ECT
Quick Inventory of Depressive Symptomatology (QIDS) and Self Reporting version (QIDS-SR) - Range 0 - 48 with higher number indicating worsening depression.

Secondary Outcome Measures

Cognitive performance
Montreal Cognitive Assessment. Measures global cognitive function. 0-30 with higher score indicates better cognitive function Dot Counting Test measures effort. Time to completion and errors recorded. Higher times/error rates indicate decreased effort Test of Premorbid Function estimates premorbid intellectual function. Negative change indicates greater cognitive & memory function impairment Autobiographical Memory Test. Free recall of retrospective autobiographical memories. 0-20 with higher score indicating improved memory function Hopkins Verbal Learning Test-Revised. Free recall, and recognition memory. Retention % calculated. Higher percentage indicates improved cognitive function Delis Kaplan Executive Function System Color-Word Interference & Verbal Fluency Test. Processing speed, sequencing and cognitive flexibility This neuropsychological battery will be used to compute composite z-scores that represent global cognitive function at each time point
Direct current electroencephalogram slow wave phenomenon (exploratory outcome)
Analysis will assess magnitude of slow-wave phenomena (area under the curve in cm^2)
ECT parameters and their correlation to production of slow-wave phenomenon
Analysis will correlate electrode placement and pulse width with production of slow-waves on dcEEG.

Full Information

First Posted
July 10, 2019
Last Updated
June 8, 2022
Sponsor
University of New Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT04022226
Brief Title
EEG Characteristics in ECT
Official Title
A Randomized Pilot Study Examining DCEEG Characteristics in Ketamine Versus Methohexital Induction in Depressed Patients Receiving Electroconvulsive Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
October 1, 2020 (Actual)
Study Completion Date
October 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of New Mexico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators will be examining slow-wave characteristics in depressed patients receiving electroconvulsive therapy (ECT) using direct current electroencephalogram (dcEEG) by anesthesia induction agent.
Detailed Description
This is a pilot project using dcEEG to look at infra-slow waves in depressed patients receiving ECT randomized to ketamine or methohexital where ketamine suppresses infra-slow waves. The rationale for this project is to identify biomarkers of treatment adequacy in ECT, which could lead to decreased morbidity and mortality with the procedure and lessen the burden of depression in our patient population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Electroconvulsive Therapy, Direct Current Electroencephalogram, Ketamine, Spreadind Depression

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methohexital
Arm Type
Active Comparator
Arm Description
Standard of care anesthesia that does not affect slow wave characteristics
Arm Title
Ketamine
Arm Type
Experimental
Arm Description
Standard of care anesthesia that suppresses slow wave characteristics
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
Induction agent that suppresses infra-slow waves
Intervention Type
Drug
Intervention Name(s)
Methohexital
Intervention Description
Induction agent that does not suppress infra-slow waves
Primary Outcome Measure Information:
Title
Clinical Efficacy of ECT
Description
Quick Inventory of Depressive Symptomatology (QIDS) and Self Reporting version (QIDS-SR) - Range 0 - 48 with higher number indicating worsening depression.
Time Frame
Outcome measures will be assessed the first, second, middle, and final ECT treatment over the course of 1 month on average for each patient. Data will be reported at 1 year.
Secondary Outcome Measure Information:
Title
Cognitive performance
Description
Montreal Cognitive Assessment. Measures global cognitive function. 0-30 with higher score indicates better cognitive function Dot Counting Test measures effort. Time to completion and errors recorded. Higher times/error rates indicate decreased effort Test of Premorbid Function estimates premorbid intellectual function. Negative change indicates greater cognitive & memory function impairment Autobiographical Memory Test. Free recall of retrospective autobiographical memories. 0-20 with higher score indicating improved memory function Hopkins Verbal Learning Test-Revised. Free recall, and recognition memory. Retention % calculated. Higher percentage indicates improved cognitive function Delis Kaplan Executive Function System Color-Word Interference & Verbal Fluency Test. Processing speed, sequencing and cognitive flexibility This neuropsychological battery will be used to compute composite z-scores that represent global cognitive function at each time point
Time Frame
Outcome measures assessed at first, second, middle, and final ECT treatment over the course of 1 month on average for each patient. Data will be reported at 1 year.
Title
Direct current electroencephalogram slow wave phenomenon (exploratory outcome)
Description
Analysis will assess magnitude of slow-wave phenomena (area under the curve in cm^2)
Time Frame
dcEEG data will be collected the first, second, middle, and final ECT treatment over the course of 1 month on average for each patient. Data will be reported at 1 year.
Title
ECT parameters and their correlation to production of slow-wave phenomenon
Description
Analysis will correlate electrode placement and pulse width with production of slow-waves on dcEEG.
Time Frame
This will be assessed throughout the year.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Structured Clinical Interview for DSM-5 will confirm diagnosis of MDD or BPD-depressed (with or without psychotic features The clinical indications for ECT including treatment resistance or a need for a rapid and definitive response; Hamilton Depression Rating Scale 24-item (HDRS-24) > 21; and Age range between 18 and 65 years of age. Exclusion Criteria: Defined neurological or neurodegenerative disorder (e.g., history of head injury with loss of consciousness > 5 minutes, epilepsy, Alzheimer's disease); Other psychiatric conditions (e.g., schizophrenia, schizoaffective disorder, bipolar disorder) Current drug or alcohol use disorder, except for nicotine and marijuana Adults unable to consent, pregnant women, prisoner Non-English speakers Patients that cannot tolerate Methohexital and Ketamine.
Facility Information:
Facility Name
University of New Mexico Mental Health Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87106
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
An embargo of 2 years will be placed on the data after Master's Thesis is published and placed into the vault to allow for publications. Afterwards, it will be available as along as the vault is maintained.
IPD Sharing Access Criteria
Pilot project is being done as a part of a Master's Thesis which will be uploaded to the University of New Mexico digital repository and may contain supporting information as above.
IPD Sharing URL
https://digitalrepository.unm.edu/

Learn more about this trial

EEG Characteristics in ECT

We'll reach out to this number within 24 hrs